The United States Food And Drug Administration (FDA) has approved a new cystic fibrosis (CF) drug combination (tezacaftor/ivacaftor) that can be used in patients who have two copies of F508del mutation (the most common CF mutation), and in patients who have at least a single copy of one of 26 specified mutations. Using this combination can treat more number of CF patients than compared to an earlier combination.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer